PDCD1 and neoplasm: A recent study highlights that the conjugated αPD-1-(iRGD)2, a PD-1 antibody-iRGD cyclic peptide conjugate developed through glycoengineering, enhances tissue penetration while simultaneously targeting tumor cells and PD-1+ T-cells.